Brief: Resonance Health Says Hepafat-Ai Receives TGA Approval
18/02/2021 01:39
Feb 18 (Reuters) - Resonance Health Ltd RHT.AX :
* HEPAFAT-AI RECEIVES TGA APPROVAL
* GOT AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL
FOR
AUTOMATED ARTIFICIAL INTELLIGENCE SOFTWARE HEPAFAT-AI
Source text for Eikon: [ID:https://bit.ly/3u6Ytvp]
Further company coverage: RHT.AX
((reuters.briefs@thomsonreuters.com))
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co